Transasia Bio-Medicals Ltd., India’s largest clinical diagnostic company has acquired Pliva Lachema Diagnostika, a 42 year old company located in Czech Republic.PLIVA Lachema Diagnostika is engaged in the development, production and marketing of In Vitro Diagnostics products consisting of a range for Urine analysis, Biochemistry and Microbiology. The company, with its extensive marketing and distribution network in the countries of Central and Eastern Europe adequately complements the current market potential and product lines of Transasia and Erba Mannheim. It has state-of-the-art manufacturing and research and development facilities at Brno, employing over 100 people.The acquisition by Transasia through its German subsidiary ERBA Diagnostics Mannheim GmbH, provides a great opportunity for Transasia and ERBA to usher in newer products in the dynamically developing markets of Asia. Also, Lachema’s customers in Central and Eastern Europe will have access to Transasia’s extensive product range in Clinical Chemistry, Immunoturbidimetry and Immunology. Transasia Bio-Medicals Ltd. and ERBA Diagnostics Mannheim plan to invest more than USD 1 Million in Lachema to increase its manufacturing capacities and add new products in the near future for meeting growing demand. This new acquisition greatly expands the spectrum of technologically advanced products and manufacturing capabilities of Transasia. Transasia and ERBA customers will now benefit with these products being offered at high quality and affordable prices. This acquisition now allows Transasia customers access to a wide range of solutions for microbiology and usher in a quicker and better diagnosis for a range of health issues, which is great news for the Indian healthcare scene. This acquisition will augment the company’s vision of bringing benefits of the best diagnostic technologies within reach for its vast populations in developing countries. The company is a partner of the Clinton foundations Aids control Program in Africa and India.